- Home
- RDHL vs JAGX Comparison
RDHL vs JAGX Comparison
Compare RDHL & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- JAGX
- Stock Information
- Founded
- RDHL 2009
- JAGX 2013
- Country
- RDHL Israel
- JAGX United States
- Employees
- RDHL N/A
- JAGX N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- RDHL Health Care
- JAGX Health Care
- Exchange
- RDHL Nasdaq
- JAGX Nasdaq
- Market Cap
- RDHL 3.9M
- JAGX 3.4M
- IPO Year
- RDHL N/A
- JAGX N/A
- Fundamental
- Price
- RDHL $1.34
- JAGX $1.80
- Analyst Decision
- RDHL
- JAGX Strong Buy
- Analyst Count
- RDHL 0
- JAGX 1
- Target Price
- RDHL N/A
- JAGX $60.00
- AVG Volume (30 Days)
- RDHL 142.3K
- JAGX 96.8K
- Earning Date
- RDHL 09-02-2025
- JAGX 08-14-2025
- Dividend Yield
- RDHL N/A
- JAGX N/A
- EPS Growth
- RDHL N/A
- JAGX N/A
- EPS
- RDHL N/A
- JAGX N/A
- Revenue
- RDHL $8,042,999.00
- JAGX $11,810,000.00
- Revenue This Year
- RDHL $381.91
- JAGX $22.41
- Revenue Next Year
- RDHL N/A
- JAGX $30.00
- P/E Ratio
- RDHL N/A
- JAGX N/A
- Revenue Growth
- RDHL 23.17
- JAGX 15.96
- 52 Week Low
- RDHL $1.06
- JAGX $1.78
- 52 Week High
- RDHL $12.50
- JAGX $35.25
- Technical
- Relative Strength Index (RSI)
- RDHL 42.30
- JAGX 33.66
- Support Level
- RDHL $1.31
- JAGX $2.02
- Resistance Level
- RDHL $1.48
- JAGX $2.65
- Average True Range (ATR)
- RDHL 0.09
- JAGX 0.18
- MACD
- RDHL 0.03
- JAGX -0.00
- Stochastic Oscillator
- RDHL 65.48
- JAGX 2.30
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.